KDR and acute myeloid leukemia: Consistently, when sorafenib (a well-known VEGFR inhibitor) was applied on MV4-11 cells, we also observed significantly cell death and decreased cell viability (Supplementary Figure S2), indicating the feasible application of quercetin as therapeutic approach for AML treatment by targeting VEGF/VEGFR2.